Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine Company’s Orbactiv), dalbavancin (Allergan’s Dalvance/Xydalba), and tedizolid (Bayer HealthCare/Merck’s Sivextro) have greatly increased treatment options for MRSA infections, making the hospital-treated MRSA market highly competitive. Within this crowded space, new agents will need to demonstrate improvements over current therapies and justify their premium pricing in light of significant competition, including that coming from generics. This report provides a comprehensive overview and analysis of the epidemiology, patient populations, and current and emerging medical practice and therapies for MRSA infections in the major pharmaceutical markets. The insights presented in this report are derived from primary and secondary research, company presentations and sales data, and detailed interviews with recognized key opinion leaders (KOLs). This report includes a 2016-2026, epidemiology-based, annualized, bottom-up forecast of current and emerging MRSA therapies in the major pharmaceutical markets.
- Because of the many agents in the HT-MRSA therapy market, understanding the positioning of these therapies in the hospital setting is essential for identifying remaining unmet needs. What do experts think about the available therapies for MRSA, and how are these agents currently used in hospital settings?
- During the forecast period, at least six new antibiotics are expected to launch, and two key MRSA drugs, linezolid and daptomycin, will continue to experience generic erosion across all major markets. Understanding the dynamics of the HT-MRSA market is key to positioning a company’s agent in this highly competitive space. Which currently available and emerging MRSA therapies are poised for commercial success over the 2016-2026 forecast period?
- The HT-MRSA infection market will be crowded; more than 20 antibiotics are included in the market forecast. Identifying unmet needs among underserved patient populations is critical to developing the appropriate strategies for commercial success. What are the areas of greatest unmet need in the MRSA market, and how will emerging brands address these needs?
- Public health agencies have always considered controlling and preventing MRSA infection one of their top priorities. As such, these agencies have developed a number of policies to target MRSA infection. Given the recent positive impact of some of these policies on drug-resistance and infection rates, such as the implementation of antimicrobial stewardship, these policies are expected to play a key role in the uptake of new antibiotics. How will changing regulatory policies regarding antibiotic use and antibiotic resistance affect the development and positioning of novel antibiotics for MRSA?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 31 country-specific interviews with infectious disease specialists.
Epidemiology: Diagnosed events of the MRSA population by country and indication, including hospital- and community-acquired MRSA.
Population segments in market forecast: Complicated skin and skin structure infections (cSSSIs) and surgical site infections (SSIs), bloodstream infections (BSIs), complicated intra-abdominal infections (cIAIs), urinary tract infections (UTIs), and nosocomial pneumonia (NP).
Emerging therapies: Phase III: 7 drugs; Phase II: 7 drugs.
- Methicillin-Resistant Staphylococcus Aureus Infections - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Jiamin Zhuo, PhD
Jiamin Zhuo, Ph.D., is a business insights analyst on the infectious, niche, and rare diseases team at Decision Resources Group. He provides expert insight into the commercial aspects of drug development and market dynamics in bacterial infections, including gram-negative infections and Methicillin-resistant Staphylococcus aureus.
He attained his Ph.D. at the Mayo Graduate School, Mayo Clinic, in Minnesota and his B.Sc. in physiology from Peking University in China. Prior to joining DRG, Dr. Zhuo was a postdoctoral fellow at Boston University and MIT, where he gained extensive experience in quantitative research methods.